期刊
PURINERGIC SIGNALLING
卷 16, 期 2, 页码 167-174出版社
SPRINGER
DOI: 10.1007/s11302-020-09694-2
关键词
Adenosine; A2A receptor; Parkinson's disease; istradefylline; KW6002; clinical trial; safety; therapy
资金
- National Natural Science Foundation of China [96018002, 80217011, 80216083]
- Wenzhou Medical University [89212012]
- Fundacion LaCaixa [HR17-00523]
- FCT [POCI-01-0145-FEDER-03127]
- Centro 2020 [CENTRO-01-0145-FEDER-000008: BrainHealth 2020, CENTRO-01-0246-FEDER-000010]
After more than two decades of preclinical and clinical studies, on August 27, 2019, the US Food and Drug Administration (FDA) approved the adenosine A(2A) receptor antagonist Nourianz (R) (istradefylline) developed by Kyowa Hakko Kirin Inc., Japan, as an add-on treatment to levodopa in Parkinson's disease (PD) with OFF episodes. This milestone achievement is the culmination of the decade-long clinical studies of the effects of istradefylline in more than 4000 PD patients. Istradefylline is the first non-dopaminergic drug approved by FDA for PD in the last two decades. This approval also provides some important lessons to be remembered, namely, concerning disease-specific adenosine signaling and targeting subpopulation of PD patients. Importantly, this approval paves the way to foster entirely novel therapeutic opportunities for adenosine A(2A) receptor antagonists, such as neuroprotection or reversal of mood and cognitive deficits in PD and other neuropsychiatric diseases.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据